|
| |
Intarcia Therapeutics, IncIntarcia Therapeutics, Inc. is a biopharmaceutical company applying a targeted approach to the acquisition, development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases.
Our highly experienced team uses its expertise in clinical medicine, pharmaceutical development and regulatory affairs to identify and develop new uses or alternative formulations for clinical stage products.
We focus especially on products that have validated mechanisms of action and existing clinical safety and activity data. We frequently combine these products with other products or technologies to create new therapeutic products that address significant market needs. We have applied this approach to create and advance our two lead clinical programs in breast cancer and Hepatitis C.
| Contact Details: |
| 2000 Powell StreetSuite 1640 |
| Emeryville |
| California |
| 94608 |
| United States of America |
| Tel: | (510) 652-2600 |
| Fax: | (510) 652-2657 |
| Email: | busdev@intarcia.com |
| WWW: | www.BIOMEDICINESINC.COM/
|
|
Loading...
|
Press Releases on Intarcia Therapeutics, Inc:
|
 |
| Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting |
6th November, 2009 |
Intarcia Therapeutics, Inc. |
HAYWARD, Calif., Nov. 6 /PRNewswire/ -- Intarcia Therapeutics, Inc. delivered two presentations today on its ITCA 650 (DUROS® continuous delivery of exenatide) program for the treatment of type 2
|
| Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference |
30th September, 2009 |
Intarcia Therapeutics, Inc. |
VIENNA, Sept. 30 /PRNewswire/ -- Intarcia Therapeutics, Inc. today presented final results from its Phase 1b clinical study of ITCA 650 (DUROS® continuous delivery of exenatide) for the treatment of
|
| Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes |
17th September, 2009 |
Intarcia Therapeutics, Inc. |
HAYWARD, Calif., Sept. 17 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the start of enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650 (DUROS continuous
|
| New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report |
7th July, 2009 |
Reportlinker |
NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue.
World Hepatitis C Virus And Therapeutics Market
http://www.reportlinker.com/p0119497/World
|
| Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions |
8th June, 2009 |
Intarcia Therapeutics, Inc. |
DUROS(R) continuous delivery of exenatide produces impressive reductions in fasting plasma glucose, HbA1c and body weight during 28-day treatment
NEW ORLEANS, June 8 /PRNewswire/ -- Intarcia
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 483 times since April 2007, the link to the organisation's website has been followed 69 times Recent Search Terms used to find this page: intarcia | intarcia | emails Intarcia Therapeutics Inc. | Intarcia Therapeutics | intarcia | Intarcia Therapeutics | OSMOTIC PUMP PATENT US 2009 | . Search for more companies in Emeryville Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Intarcia Therapeutics, Inc |
